Cancer cells can treat tumors

Cancer cells can treat tumors.


New explore suggests that many cancer cells are equipped with a big-hearted of suicide pill: a protein on their surfaces that gives them the ability to send an "eat me" conspicuous to immune cells. The challenge now, the researchers say, is to presence out how to coax cancer cells into emitting the signal rather than a dangerous "don't eat me" signal venta de anfepramona en chile. A investigate published online Dec 22 2010 in Science Translational Medicine reports that the cells fire out the enticing "eat me" signal by displaying the protein calreticulin.



But another molecule, called CD47, allows most cancer cells to keep off destruction by sending the antithesis signal: "Don't eat me". In earlier research, Stanford University School of Medicine scientists found that an antibody that blocks CD47 - turning off the gesticulate - could inform fight cancer, but mysteries remained i found it. "Many normal cells in the body have CD47, and yet those cells are not distressed by the anti-CD47 antibody," Mark Chao, a Stanford graduate student and the study's lead author, said in a university bulletin release.



And "At that time, we knew that anti-CD47 antibody therapy selectively killed only cancer cells without being toxic to most normal cells, although we didn't know why". Now, the redone research has shown that calreticulin exists in a variety of cancers, including some types of leukemia, non-Hodgkin's lymphoma and bladder, discernment and ovarian cancers.



So "This research demonstrates that the end that blocking the CD47 'don't eat me' signal works to kill cancer is that leukemias, lymphomas and many upstanding tumors also display a calreticulin 'eat me' signal," Dr Irving Weissman, numero uno of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and a co-principal investigator of the study, said in the release. "The experiment with also shows that most normal cell populations don't presentation calreticulin and are, therefore, not depleted when we expose them to a blocking anti-CD47 antibody".



The next stage is to understand how calreticulin works. "We want to know how it contributes to the disease process and what is chance in the cell that causes the protein to move to the cell surface," Dr Ravindra Majeti, an aide professor of hematology and study co-principal investigator, said in the release recommended site. "Any of these mechanisms sell potential new ways to treat the disease by interfering with those processes".

tag : cells cancer signal calreticulin antibody normal study release protein

Post a comment

Private comment

Профиль

alejandrafalto

Author:alejandrafalto
Dr. Alejandra Falto

Новые записи
Новые комментарии
Новые трэкбэки
Архив по месяцам
Категории
Форма поиска
RSS ссылка
Ссылки
Формуляр приглашения в блог-друзья

Добавить автора в блог-друзья